There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rallybio (RLYB – Research Report), Agile Therapeutics (AGRX – Research Report) and Biomea Fusion (BMEA – Research Report) with bullish sentiments.
Rallybio (RLYB)
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Rallybio today and set a price target of $18.00. The company’s shares closed last Friday at $8.14.
According to TipRanks.com, Kapoor is a 3-star analyst with an average return of
Rallybio has an analyst consensus of Strong Buy, with a price target consensus of $17.00, implying a 121.1% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $16.00 price target.
See today’s best-performing stocks on TipRanks >>
Agile Therapeutics (AGRX)
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Agile Therapeutics, with a price target of $12.00. The company’s shares closed last Friday at $2.81, close to its 52-week low of $2.75.
According to TipRanks.com, Livnat is a 2-star analyst with an average return of
Agile Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
Biomea Fusion (BMEA)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Biomea Fusion today and set a price target of $50.00. The company’s shares closed last Friday at $30.67.
According to TipRanks.com, Pantginis is a 3-star analyst with an average return of
Biomea Fusion has an analyst consensus of Strong Buy, with a price target consensus of $51.00, implying a 58.0% upside from current levels. In a report issued on June 20, J.P. Morgan also maintained a Buy rating on the stock with a $38.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
